Gennex Laboratories Ltd
BSE:531739
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gennex Laboratories Ltd
Gross Profit
Gennex Laboratories Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gennex Laboratories Ltd
BSE:531739
|
Gross Profit
₹439.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Gross Profit
₹228.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Gross Profit
₹188.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Gross Profit
₹454.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Gross Profit
₹189.9B
|
CAGR 3-Years
26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Gross Profit
₹96.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Gennex Laboratories Ltd
Glance View
Gennex Laboratories Ltd. engages in the manufacture of bulk drugs and intermediates products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing of bulk drugs, intermediaries and biotech products. The firm has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The firm operates through Pharmaceutical Products (Bulk Drugs) segment. The firm's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The firm has manufacturing facilities in India which caters to both domestic and international markets.
See Also
What is Gennex Laboratories Ltd's Gross Profit?
Gross Profit
439.1m
INR
Based on the financial report for Dec 31, 2025, Gennex Laboratories Ltd's Gross Profit amounts to 439.1m INR.
What is Gennex Laboratories Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
12%
Over the last year, the Gross Profit growth was 5%. The average annual Gross Profit growth rates for Gennex Laboratories Ltd have been 20% over the past three years , 7% over the past five years , and 12% over the past ten years .
